[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611653":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nanocrystalline Megestrol Acetate Oral Suspension + Standard Antitumor Therapy","EXPERIMENTAL","This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study and are scheduled to receive treatment with nanocrystalline megestrol acetate.",[13],"Drug: Nanocrystalline Megestrol Acetate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Nanocrystalline Megestrol Acetate","Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg\u002FmL, administered orally at a dose of 5 mL per day (625 mg\u002Fday), and the primary endpoint efficacy collection will be conducted in the 4th week.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Suxia Luo","CONTACT","18638553211","luosxrm@163.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Henan Cancer Hospital, Affiliated to Zhengzhou University","RECRUITING","Zhengzhou","Henan","45000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],113.64861,34.75778,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[47],{"name":48,"class":49},"Henan Cancer Hospital","OTHER_GOV","100611653","phase-4-a-prospective-real-world-observational-study-of-nanocrystalline-megestrol-acetate-in-patients-with-cancer-cachexia-100611653",false,"NCT07243379","A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","Inclusion Criteria:\n\n* Patients with histologically and\u002For cytologically confirmed malignancy.\n* Age ≥18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of ≥3 months.\n* Meeting the diagnostic criteria for cachexia (based on Fearon's criteria).\n* Body mass index (BMI) ≤30.\n\nExclusion Criteria:\n\n* Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.\n* Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.\n* Patients with acquired immunodeficiency syndrome (AIDS).\n* Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n* Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.","ALL","18 Years","85 Years",{"count":60,"type":61},495,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.",[67,68],"Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia","Multicenter Observational Study","2025-11-19",{"date":71,"type":72},"2025-11-21","ACTUAL",{"date":74,"type":72},"2025-09-25",{"date":76,"type":61},"2027-06-30",{"name":5,"class":6},1]